ALERS — Eurobio Scientific SA Share News
0.000.00%
Last trade - 00:00- €253.72m
- €241.20m
- €168.60m
Brief: Diaxonhit H1 consolidated revenues decrease to 15.0 million euros
Brief: Diaxonhit and ABL announce distribution agreement for HIV and HCV genotyping by NGS sequencing
Brief: Diaxonhit ends patient enrollment in European CITHY clinical validation study
Brief: Diaxonhit widens FY net loss to 5.9 million
Brief: Diaxonhit FY revenue down at 29.5 mln euros
Brief: Diaxonhit and CareDx successfully transfer AlloMap test to Europe
Brief: Diaxonhit enrolls 1000th patient in DX15 study
Brief: Diaxonhit to issue 1,798,000 new ordinary shares on Alternext Paris
Brief: Diaxonhit H1 net loss widens to 2.3 million euros
Brief: Diaxonhit announces encouraging results of study of vaccine against HIV
Brief: Diaxonhit H1 consolidated revenue stable at 15.8 mln euros
Brief: Diaxonhit receives $0.5 million payment from Allergan
Brief: Clinical utility and performance of Diaxonhit's AlloMap confirmed
Brief: Diaxonhit grants Felicitex global exclusive license
Brief: Diaxonhit FY net loss declines to 5.5 mln euros
Brief: Diaxonhit FY revenue grows to 30.6 mln euros
Brief: Diaxonhit announces CE marking of BJI InoPlex test
Brief: Diaxonhit agrees service sub-licensing agreement with Strasbourg University Hospitals
Brief: Diaxonhit to issue 24,483 new ordinary shares - Euronext